stockportfolio.pro
Stocks / NKTR vs NVCR
NKTR vs NVCR
Nektar Therapeutics and NovoCure Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Nektar Therapeutics (NKTR) | NovoCure Limited (NVCR) | |
|---|---|---|
| Market cap | $2.0B | $1.9B |
| Revenue (latest FY) | $55.23M | $655.35M |
| Net income (latest FY) | $-164.08M | $-136.23M |
| Revenue growth (5y CAGR) | -18.4% | 5.8% |
| Net margin | -297.1% | -20.8% |
| Return on equity | -182.6% | -40.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NKTR — free Open NVCR — freeFrequently asked questions
Which is bigger, NKTR or NVCR?
Nektar Therapeutics is larger by market capitalization — $2.0B versus $1.9B.
Which grows faster, NKTR or NVCR?
Over the last five fiscal years, NovoCure Limited grew revenue faster — 5.8%/yr versus -18.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.